Jacqueline Zummo insider trades: Protara Therapeutics (TARA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jacqueline reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | TARA | ↓ Sell10b5-1 | 1,134 | $5.40 | $6K | Direct | Apr 9, 2026 (1d) |
| Apr 1, 2026 | TARA | ↓ Sell10b5-1 | 22,598 | $5.26 | $119K | Direct | Apr 2, 2026 (1d) |
| Mar 26, 2025 | TARA | ↓ Sell10b5-1 | 21,224 | $4.53 | $96K | Direct | Mar 28, 2025 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TARA insiders
Open-market trades in the last 12 months
About Jacqueline Zummo's insider trades
Jacqueline Zummo is Chief R&D Officer at Protara Therapeutics (TARA). Since Mar 26, 2025, Jacqueline has reported no open-market purchases and 3 sales worth $221K on SEC Form 4. In the last 12 months: 2 sales ($125K).
3 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include shares withheld for taxes (11 filings), grants and awards (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TARA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.